CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Appearance before the House of Commons Standing Committee on Health
https://policybase.cma.ca/link/policy14475

POLICY TYPE  Parliamentary submission
DATE  2022-05-09
TOPICS  Health systems, system funding and performance
  Ethics and medical professionalism

Documents

Appearance before the House of Commons Standing Committee on Health

Dr. Katharine Smart
President of the Canadian Medical Association
May 9, 2022

(Canadian Medical Association logo)
Appearance before the Standing Committee on Indigenous and Northern Affairs (INAN): Administration and accessibility of Indigenous Peoples to the Non-Insured Benefits Program

https://policybase.cma.ca/link/policy14474

POLICY TYPE
Parliamentary submission

DATE
2022-05-03

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents

Appearance before the Standing Committee on Indigenous and Northern Affairs (INAN): Administration and accessibility of Indigenous Peoples to the Non-Insured Benefits Program

Dr. Alba Lafontaine
President, Board of the Canadian Medical Association

May 4, 2022

[Document image]
Health Human Resource Policy Recommendations: Summary. Briefing to the House of Commons Standing Committee on Health
https://policybase.cma.ca/link/policy14473

POLICY TYPE
Parliamentary submission

DATE
2022-04-14

TOPICS
Health systems, system funding and performance
Ethics and medical professionalism

Documents
Study on Canada’s Health Workforce
https://policybase.cma.ca/link/policy14469

POLICY TYPE
Parliamentary submission

DATE
2022-02-16

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents

Appearance before the House of Commons Standing Committee on Health:

Study on Canada’s Health Workforce

Dr. Corky Burson
President of the Canadian Medical Association
February 18, 2022
10:30 a.m. - 4:00 p.m.
Recommendations for federal action to address Canada’s health care crisis
https://policybase.cma.ca/link/policy14468

POLICY TYPE
Parliamentary submission

DATE
2022-02-15

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents
Study on Bill S-209, An Act respecting Pandemic Observance Day

https://policybase.cma.ca/link/policy14467

POLICY TYPE
Parliamentary submission

DATE
2022-02-09

TOPICS
Health care and patient safety
Ethics and medical professionalism

Documents

Appearance before the Senate Standing Committee on Social Affairs, Science and Technology

Study on Bill S-209, An Act respecting Pandemic Observance Day

Dr. Jürgen Grönig
President of the Canadian Medical Association

February 09, 2022
(Declaration of Interest)
CMA Submission to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities’ study of Bill C-3, An Act to amend the Criminal Code and the Canada Labour Code

https://policybase.cma.ca/link/policy14464

POLICY TYPE
Parliamentary submission

DATE
2021-12-15

TOPICS
Health care and patient safety
Ethics and medical professionalism
CMA Submission to the Standing Committee on Social Affairs, Science and Technology’s study of Bill C-3, An Act to amend the Criminal Code and the Canada Labour Code

https://policybase.cma.ca/link/policy14462

POLICY TYPE
Parliamentary submission

DATE
2021-12-10

TOPICS
Ethics and medical professionalism

Documents
Canadian Medical Association input in advance of the World Health Assembly Special Session
https://policybase.cma.ca/link/policy14461

POLICY TYPE
Parliamentary submission

DATE
2021-11-17

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents
New Criminal Code offence to protect health workers from threats and violence, including online
https://policybase.cma.ca/link/policy14463

POLICY TYPE  Parliamentary submission
DATE  2021-11-16
TOPICS  Population health, health equity, public health
Ethics and medical professionalism

Documents
Canada’s doctors and nurses urgently calling for federal measures to address Canada’s health workforce crisis

https://policybase.cma.ca/link/policy14460

POLICY TYPE  Parliamentary submission
DATE  2021-11-09
TOPICS  Ethics and medical professionalism
Disclosure of COVID-19 Vaccination Status by Physicians

https://policybase.cma.ca/link/policy14457

POLICY TYPE
Policy document

DATE
2021-10-22

TOPICS
Physician practice, compensation, forms

Disclosure of COVID-19 Vaccination Status by Physicians

In order to protect patients, physicians may need to disclose their vaccination status to patients in order to provide informed consent or to care for patients. In these situations, physicians may be required to disclose their vaccination status to patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

1. The RCPMCC encourages physicians to disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

2. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

3. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

4. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

5. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

6. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

7. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

8. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

9. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.

10. Physicians may disclose their vaccination status to patients in order to provide informed consent or to care for patients. Physicians may also voluntarily disclose their vaccination status to patients in order to inform patients about the benefits and potential risks of vaccination.
COVID-19 Vaccine Global Intellectual Property Policy

Policy positions recommendation

1. The CMA encourages the Government of Canada to participate in the global dialogue, taking the lead in tackling vaccine availability, affordability, and accessibility issues. The CMA, along with other national and international medical associations, should actively engage in shaping the global intellectual property landscape to facilitate equitable access to COVID-19 vaccines.

2. The CMA encourages the Government of Canada to support the implementation of a transparent, multilateral, and equitable global intellectual property patent pool that can facilitate the sharing of intellectual property rights to COVID-19 vaccines.

3. The CMA encourages the Government of Canada to support initiatives that promote the open sharing of vaccine data and information to ensure that all countries have access to the latest research and best practices in vaccine development and distribution.

4. The CMA encourages the Government of Canada to support the development of a global framework that prioritizes public health and global health security, ensuring that intellectual property rights do not hinder the delivery of vaccines to low-income countries.

5. In the event of a pandemic, the CMA recommends that the Government of Canada work with international partners to ensure that vaccines are developed and distributed in a timely manner, taking into account the needs of all countries. This includes supporting research and development efforts, ensuring that intellectual property rights are managed in a way that minimizes barriers to access.

6. The CMA encourages the Government of Canada to support global initiatives that aim to reduce the burden of intellectual property rights on public health, such as the proposed waiver on intellectual property rights under the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) during public health emergencies.

7. The CMA encourages the Government of Canada to work with international partners to ensure that intellectual property rights are managed in a way that minimizes barriers to access, while also protecting the innovation that is essential for public health.

8. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

9. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

10. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

11. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

12. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

13. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

14. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

15. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

16. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

17. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

18. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

19. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

20. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

21. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

22. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

23. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

24. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

25. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

26. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

27. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

28. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

29. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

30. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

31. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

32. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

33. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

34. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

35. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

36. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

37. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

38. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

39. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

40. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

41. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

42. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

43. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

44. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

45. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

46. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

47. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

48. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

49. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.

50. The CMA encourages the Government of Canada to support the development of policies that ensure that intellectual property rights are managed in a way that prioritizes public health and global health security, ensuring that vaccines are available to all who need them.
Vaccine certificates

https://policybase.cma.ca/link/policy14448

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents
Global vaccine equity

https://policybase.cma.ca/link/policy14451

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Ethics and medical professionalism
Population health, health equity, public health
Guidelines for physicians in interactions with industry / Recommendations for physician innovators

https://policybase.cma.ca/link/policy14454

POLICY TYPE
Policy document

DATE
2021-08-21

REPLACES
PD08-01 Guidelines for Physicians in Interactions with Industry

TOPICS
Ethics and medical professionalism

Guidelines for physicians in interactions with industry

See also companion policy Recommendations for physician innovators.

Recommendations: Physicians are working with an increasing number of industry sponsors in various capacities. Physicians should maintain their professional independence and be aware of potential conflicts of interest. These recommendations are intended to help physicians maintain their professional integrity and avoid conflicts of interest. The guidelines are based on the recommendations of the Council of Ethics of the American Medical Association (AMA) and the Canadian Medical Association (CMA). The guidelines are intended to help physicians maintain their professional integrity and avoid conflicts of interest.

Recommendations for Physician Innovators

See also companion policy Guidelines for physicians in interactions with industry.

Physicians—an increasing number of whom are leading innovators in entrepreneurship—can establish an industry relationship that is mutually beneficial. However, physicians should maintain their professional independence and avoid conflicts of interest. The recommendations are intended to help physicians maintain their professional integrity and avoid conflicts of interest. The guidelines are based on the recommendations of the Council of Ethics of the American Medical Association (AMA) and the Canadian Medical Association (CMA). The guidelines are intended to help physicians maintain their professional integrity and avoid conflicts of interest.